<DOC>
	<DOCNO>NCT00883181</DOCNO>
	<brief_summary>The primary objective describe incidence febrile neutropenia base granulocyte-colony stimulating factor ( G-CSF ) use ( primary , secondary , treatment , usage ) patient receive myelotoxic chemotherapy .</brief_summary>
	<brief_title>A Study Neutropenia Anemia Management Patients With Solid Tumors Receiving Myelotoxic Chemotherapy</brief_title>
	<detailed_description>This multi-center international observational study patient receive myelotoxic regimen , investigator assess risk febrile neutropenia ≥ 20 % , treatment solid tumor ( breast , ovarian lung ) . This observational study patient risk factor qualitatively ( quantitatively ) assess , adherence G-CSF primary prophylaxis discretion physician mandate protocol .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Subjects great equal 18 year old breast , ovarian lung cancer receive chemotherapy schedule , e.g . dose dense standard chemotherapy . These subject must Investigator assess risk febrile neutropenia ( FN ) ≥20 % ( base 2006 European Organisation Research Treatment Cancer ( EORTC ) GCSF Guidelines Subjects concurrent administration radiotherapy eligible ( previous radiotherapy permit terminate least 2 week prior commence applicable chemotherapy study ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>